Loading
GT
Guided Therapeutics Inc Stock: price and insider trades · United States
US·Mcap US$14.5M
No insider purchase over the last 90 days. The latest, by Grujic Alan, was filed 05 Sept 2025.
Guided Therapeutics Inc: what insiders have been doing
Guided Therapeutics Inc is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 24 October 2026, 1 filing were filed, from 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
For context, the typical company on the same exchange (median of 282 companies) published 8 filings over the same period, against 1 filing here. Our records for Guided Therapeutics Inc go back to 2006, with 31 purchases and 58 sales on the open market in total.
Insider buying of Guided Therapeutics Inc has been absent for the past year.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
388
Thresholds
n/a
Buy Volume
€776,181
31 ops. · all time
Sell Volume
€219,211
58 ops. · all time
Who traded when
BuySaleAlan Grujic1 buy
John E. Imhoff1 buy
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.15
Analyst consensus
Income statement
RevenueUS$767k
Gross profitUS$571k74% margin
EBITDA-US$2.5M-322% margin
Net income-US$3.2M-416.7% margin
Valuation
Beta0.70
Balance sheet & cash
Market capUS$14.5M
Total debtUS$2.9M
Free Cash Flow-US$1.1M
Profitability & ownership
ROA-115.6%
% insiders36.5%
% institutions0.0%
Last declaration on 4 March 2026
Declarations388 total
100,000 sharesCommon StockSEC:0001477932-26-001162:0
165,481 sharesCommon StockSEC:0001477932-25-006522:0
55,853 sharesCommon StockSEC:0001477932-25-006522:1
81,121 sharesCommon StockSEC:0001477932-25-006522:2
233 sharesPreferred Series E StockSEC:0001477932-25-006522:3
932,000 sharesCommon StockSEC:0001477932-25-006522:4
17,408 sharesCommon StockSEC:0001477932-25-006531:0
50 sharesPreferred Series E StockSEC:0001477932-25-006531:1
200,000 sharesCommon StockSEC:0001477932-25-006531:2
152,108 sharesCommon StockSEC:0001477932-25-006531:3
Canonical exit: 27 Nov 2025 (T+90)
35,312 sharesCommon StockSEC:0001477932-25-001072:0
1,615,385 sharesCommon StockSEC:0001477932-24-008256:0
Canonical exit: 18 Mar 2025 (T+90)
36,161 sharesCommon StockSEC:0001477932-24-006671:0
400,000 sharesCommon StockSEC:0001477932-24-006656:0
1,666,667 sharesCommon StockSEC:0001477932-24-006161:0
Canonical exit: 22 Dec 2024 (T+90)
36,602 sharesCommon StockSEC:0001477932-24-005227:0
183,008 sharesCommon StockSEC:0001477932-24-005207:0
170,563 sharesCommon StockSEC:0001477932-24-005206:0
48,327 sharesCommon StockSEC:0001477932-24-004509:0
4,420 sharesCommon StockSEC:0001477932-24-002247:0
48,638 sharesCommon StockSEC:0001477932-24-002247:1
114,912 sharesCommon stockSEC:0001477932-24-001900:0
38,893 sharesCommon stockSEC:0001477932-24-001900:1
400,000 sharesCommon stockSEC:0001477932-24-001435:0
37,410 sharesCommon StockSEC:0001477932-24-000856:0
25 of 388 declarations
About Guided Therapeutics Inc
Guided Therapeutics Inc is a company focused on developing medical technologies for the diagnosis and treatment of diseases. It is listed on the XNAS market.
